Arginyl-glycyl-aspartic acid (RGD) containing nanostructured lipid carrier co-loaded with doxorubicin and sildenafil citrate enhanced anti-cancer effects and overcomes drug resistance

2019 ◽  
Vol 84 ◽  
pp. 172-179 ◽  
Author(s):  
Hamed Hajipour ◽  
Marjan Ghorbani ◽  
Houman Kahroba ◽  
Farideh Mahmoodzadeh ◽  
Reza Zolfaghari Emameh ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Aspartic Acid ◽  
Sildenafil Citrate ◽  
Nanostructured Lipid Carrier ◽  
Anti Cancer

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance

2009 ◽  
Vol 3 (1) ◽  
pp. 89-99 ◽  
Author(s):  
Tim Kwok ◽  
Siu Kong ◽  
Ming Li ◽  
Ho Ho ◽  
Bao Yu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Multi Drug Resistance ◽  
Anti Cancer ◽  
Hepatocarcinoma Cells ◽  
Cancer Agent ◽  
Polyphyllin D

Nuclear delivery of dual anti-cancer drugs by molecular self-assembly

2021 ◽  
Vol 9 (1) ◽  
pp. 116-123
Author(s):  
Jindao Wu ◽  
Wenzhou Ding ◽  
Guoyong Han ◽  
Wei You ◽  
Wen Gao ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Tumor Cells ◽  
Self Assembly ◽  
Nuclear Accumulation ◽  
Cancer Drugs ◽  
Anti Cancer ◽  
Good Cell

Nanomedicines generally suffer from poor accumulation in tumor cells, low anti-tumor efficacy, and drug resistance. In order to address these problems, we introduced a novel nanomedicine based on dual anti-cancer drugs, which showed good cell nuclear accumulation properties.

Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance

2019 ◽  
Vol 171 ◽  
pp. 104-115 ◽  
Author(s):  
Yuxuan Dai ◽  
Xingguang Cai ◽  
Xinzhou Bi ◽  
Chunxia Liu ◽  
Na Yue ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Folic Acid ◽  
Anti Cancer

The role of microvesicles in cancer progression and drug resistance

2013 ◽  
Vol 41 (1) ◽  
pp. 293-298 ◽  
Author(s):  
Samireh Jorfi ◽  
Jameel M. Inal
Keyword(s):  
Drug Resistance ◽  
Multidrug Resistance ◽  
Cancer Progression ◽  
Chemotherapeutic Agents ◽  
Malignant Cells ◽  
Intercellular Transport ◽  
Wide Range ◽  
Anti Cancer ◽  
Mdr Multidrug Resistance

Microvesicles are shed constitutively, or upon activation, from both normal and malignant cells. The process is dependent on an increase in cytosolic Ca2+, which activates different enzymes, resulting in depolymerization of the actin cytoskeleton and release of the vesicles. Drug resistance can be defined as the ability of cancer cells to survive exposure to a wide range of anti-cancer drugs, and anti-tumour chemotherapeutic treatments are often impaired by innate or acquired MDR (multidrug resistance). Microvesicles released upon chemotherapeutic agents prevent the drugs from reaching their targets and also mediate intercellular transport of MDR proteins.

Sign in / Sign up

Export Citation Format

Share Document